{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T09:58:08Z","timestamp":1720000688506},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.medcli.2010.09.035","type":"journal-article","created":{"date-parts":[[2011,2,6]],"date-time":"2011-02-06T09:09:59Z","timestamp":1296983399000},"page":"8-13","source":"Crossref","is-referenced-by-count":9,"title":["Tratamiento de la hemoglobinuria parox\u00edstica nocturna con eculizumab: experiencia en Espa\u00f1a"],"prefix":"10.1016","volume":"137","author":[{"given":"Montserrat","family":"L\u00f3pez Rubio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Morado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Gaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dora","family":"Alonso Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Ojeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Antonio","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bego\u00f1a","family":"P\u00e9rez de Mendiguren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Dolores","family":"Monteagudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Dur\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa Mar\u00eda","family":"Fisac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dami\u00e1n","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Mar\u00eda","family":"Villegas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2010.09.035_bib0005","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2010.09.035_bib0010","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2010.09.035_bib0015","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199511093331904","article-title":"Natural history of paroxysmal nocturnal hemoglobinuria","volume":"333","author":"Hillmen","year":"1995","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2010.09.035_bib0020","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1182\/blood-2008-01-133918","article-title":"Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories","volume":"112","author":"De Latour","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2010.09.035_bib0025","doi-asserted-by":"crossref","unstructured":"Kelly R, Richards S, Arnold L, Valters G, Cullen M, Hill A, et al. A spontaneous reduction of clone size in paroxysmal nocturnal hemoglobinuria patients treated with eculizumab for greater than 12 months. Blood (ASH Annual Meeting Abstracts). 2009. Abstract 1992.","DOI":"10.1182\/blood.V114.22.1992.1992"},{"key":"10.1016\/j.medcli.2010.09.035_bib0030","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1157\/13127921","article-title":"Hemoglobinuria parox\u00edstica nocturna","volume":"131","author":"Hern\u00e1ndez Campo","year":"2008","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.medcli.2010.09.035_bib0035","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.medcli.2009.09.026","article-title":"Hemoglobinuria parox\u00edstica nocturna: nuevos tratamientos y recomendaciones generales para su diagn\u00f3stico","volume":"134","author":"Morado","year":"2010","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.medcli.2010.09.035_bib0040","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2141.2004.04992.x","article-title":"Natural history of paroxysmal nocturnal haemoglobinuria using modern diagnostic assays","volume":"126","author":"Moyo","year":"2004","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2010.09.035_bib0045","doi-asserted-by":"crossref","unstructured":"Muus P, Risitano AM, Castro-Malaspina HR, Jones M, Fuller S, Socie G. Clinical impact of unregulated terminal complement activity in never-transfused patients with paroxysmal nocturnal hemoglobinuria. Blood (ASH Annual Meeting Abstracts). 2009. Abstract 4029.","DOI":"10.1182\/blood.V114.22.4029.4029"},{"key":"10.1016\/j.medcli.2010.09.035_bib0050","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1046\/j.1365-2141.2001.03127.x","article-title":"Multilineage glycosylphosphatidylinositol anchor deficient hematopoiesis in untreated aplastic anemia","volume":"115","author":"Mukhina","year":"2001","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2010.09.035_bib0055","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1034\/j.1600-0609.2001.00376.x","article-title":"Relative increase of granulocytes with a paroxysmal nocturnal haemoglobinuria phenotype in aplastic anaemia patients: the high prevalence at diagnosis","volume":"66","author":"Wang","year":"2001","journal-title":"Eur J Haematol."},{"key":"10.1016\/j.medcli.2010.09.035_bib0060","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2141.1988.tb02382.x","article-title":"Late haematological complications in severe aplastic anaemia","volume":"69","author":"Tichelli","year":"1998","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2010.09.035_bib0065","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2141.1989.tb00230.x","article-title":"Long-term follow-up of severe aplastic anaemia patients treated with antithymocyte globulin. Severe Aplastic Anaemia Working Party of the European Cooperative Group for Bone Marrow Transplantation (EBMT)","volume":"73","author":"De Planque","year":"1989","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2010.09.035_bib0070","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1056\/NEJM199310143291603","article-title":"Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party","volume":"329","author":"Socie","year":"1993","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2010.09.035_bib0075","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","article-title":"Effect on the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria","volume":"110","author":"Hillmen","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2010.09.035_bib0080","doi-asserted-by":"crossref","unstructured":"Hillmen P. The role of complement inhibition in PNH. Hematology American Society Hematology Educational Program. 2008;116\u201323","DOI":"10.1182\/asheducation-2008.1.116"},{"key":"10.1016\/j.medcli.2010.09.035_bib0085","doi-asserted-by":"crossref","unstructured":"Socie G, Muus P, Schrezenmeier H, Maciejewsky J, Weitz I, Hill A, et al. Terminal complement inhibitor eculizumab improves complement-mediated platelet consumption and thrombocytopenia in patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood (ASH Annual Meeting Abstracts). 2009. Abstract 4030.","DOI":"10.1182\/blood.V114.22.4030.4030"},{"key":"10.1016\/j.medcli.2010.09.035_bib0090","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.1053\/ajkd.2001.21361","article-title":"Reversible renal failure in paroxysmal nocturnal hemoglobinuria","volume":"37","author":"Chow","year":"2001","journal-title":"Am J Kidney Dis."},{"key":"10.1016\/j.medcli.2010.09.035_bib0095","first-page":"172","article-title":"Acute renal failure in a patient with paroxysmal nocturnal hemoglobinuria","volume":"56","author":"Jose","year":"2001","journal-title":"Clin Nephrol."},{"key":"10.1016\/j.medcli.2010.09.035_bib0100","doi-asserted-by":"crossref","unstructured":"Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, et al. Chronic renal insufficiency in Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH): Improvement with eculizumab treatment in the long-term follow-up of the AEGIS Study. Blood (ASH Annual Meeting Abstracts). 2009. Abstract 1980.","DOI":"10.1182\/blood.V114.22.1980.1980"},{"key":"10.1016\/j.medcli.2010.09.035_bib0105","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1182\/blood-2005-02-0564","article-title":"Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"106","author":"Hill","year":"2005","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2010.09.035_bib0110","first-page":"3770","article-title":"Effect of the terminal complement inhibitor eculizumab on patient reported outcomes in paroxysmal nocturnal hemoglobinuria (PNH): phase III Triumph study results","volume":"108","author":"Brodsky","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)."},{"key":"10.1016\/j.medcli.2010.09.035_bib0115","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicentric phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2010.09.035_bib0120","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(09)60001-5","article-title":"Eculizumab for paroxysmal nocturnal haemoglobinuria","volume":"373","author":"Parker","year":"2009","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2010.09.035_bib0125","unstructured":"Parker C. Ask the hematologist. How do I diagnose and treat PNH? The Hematologist. 2008;5:4-5."},{"key":"10.1016\/j.medcli.2010.09.035_bib0130","doi-asserted-by":"crossref","first-page":"6522","DOI":"10.1182\/blood-2009-03-195966","article-title":"How I treat paroxysmal nocturnal hemoglobinuria","volume":"113","author":"Brodsky","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2010.09.035_bib0135","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1182\/blood-2008-11-189944","article-title":"Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab","volume":"113","author":"Risitano","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2010.09.035_bib0140","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.3324\/haematol.10836","article-title":"Erythropoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria","volume":"92","author":"Hill Al","year":"2007","journal-title":"Haematologica."},{"key":"10.1016\/j.medcli.2010.09.035_bib0145","doi-asserted-by":"crossref","unstructured":"Schrezenmeier H, Schubert J, Luzzatto L, Muus P, Socie G, Risitano AM, et al. Effects of eculizumab therapy in patients with paroxysmal nocturnal hemoglobinuria (PNH) receiving concurrent immunosuppressive therapy for bone marrow insufficiency. Blood (ASH Annual Meeting Abstracts). 2009. Abstract 3012.","DOI":"10.1182\/blood.V114.22.3012.3012"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775310009991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775310009991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T09:09:34Z","timestamp":1592298574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775310009991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0025775310009991"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2010.09.035","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}